Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimal Target of Activated Clotting Time During Percutaneous Coronary Intervention and Outcomes: The Randomized OPTIMAL-ACT Trial

NCT03772613 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT03772613
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03772613 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimal Target of Activated Clotting Time During Percutaneous Coronary Intervention and Outcomes: The Randomized OPTIMAL-ACT Trial
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Completed
Start date
February 8, 2019
Completion date
October 25, 2021
Enrollment
180 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anticoagulant-induced bleeding, coronary artery disease, coronary syndrome, ischemic heart disease